Aspergillus fumigatus

Aspergillus fumigatus is a **filamentous fungus** widely distributed in the environment, notably in soil and decaying organic matter, where it functions as a saprotroph, contributing to carbon and nitrogen recycling[1][3]. Its spores (conidia) are small, become airborne easily, and are inhaled daily by humans and animals; healthy individuals eliminate them through immune responses, but immunocompromised hosts are highly vulnerable to infection. A. fumigatus is the most common cause of **aspergillosis**, ranging from allergic reactions and chronic lung infection to quickly fatal invasive disease[1][5][7]. Current antifungal therapies focus on inhibiting essential fungal genes (e.g., ergosterol biosynthesis), but emerging drug resistance and the fungus’s adaptability present major therapeutic challenges[2][6][8]. Recent experimental strategies such as CAR T cells targeting fungal antigens are being developed as advanced therapies for severe, drug-resistant infections[4]. A. fumigatus is **not a canonical molecular target** but is the disease-causing organism, so information about specific molecular targets within A. fumigatus (e.g., ERG11) should be referenced when discussing actionable therapeutic targets[2][6][8].

Other names

Aspergillus fumigatusA. fumigatus

Azole antifungals (voriconazole, itraconazole, posaconazole, isavuconazole): inhibit ergosterol biosynthesis (target ERG11 gene family – lanosterol 14α-demethylase). Amphotericin B: binds to ergosterol and disrupts fungal cell membranes. Echinocandins: inhibit β-1,3-glucan synthesis in the fungal cell wall. Af-CAR T cells: targeted immunotherapy using engineered T cells to recognize and kill fungal hyphae.